Zacks Investment Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Zacks Investment Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,744	Closed	-$127K	–	635
2017 Q4	$127K	Buy	+1,744	New	+$144K	﹤0.01%	547
2017 Q2	–	Sell	-1,023	Closed	-$222K	–	701
2017 Q1	$222K	Buy	+1,023	New	+$146K	0.01%	554
2016 Q3	–	Sell	-2,685	Closed	-$272K	–	736
2016 Q2	$272K	Buy	2,685 +56	+2%	+$6.94K	0.01%	510
2016 Q1	$431K	Buy	2,629 +534	+25%	+$108K	0.01%	457
2015 Q4	$686K	Sell	2,095 -407	-16%	-$132K	0.02%	370
2015 Q3	$807K	Buy	2,502 +624	+33%	+$274K	0.03%	339
2015 Q2	$748K	Sell	1,878 -52	-3%	-$22.1K	0.02%	358
2015 Q1	$950K	Sell	1,930 -525	-21%	-$203K	0.03%	301
2014 Q4	$878K	Sell	2,455 -812	-25%	-$242K	0.03%	294
2014 Q3	$630K	Buy	3,267 +257	+9%	+$56.5K	0.02%	349
2014 Q2	$719K	Buy	+3,010	New	+$612K	0.03%	332

Other funds holding LUMO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Zacks Investment Management's LUMO Position: Q1 2018 in Review

Zacks Investment Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2018, closing a stake of 1,744 shares — an estimated $127K sold.

Zacks Investment Management first reported a position in LUMO in Q2 2014 and held it in 11 quarters. The position peaked at $950K in Q1 2015. 126 funds tracked by Wall St. Rank hold LUMO as of Q1 2018.

Zacks Investment Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Zacks Investment Management sold 1,744 Lumos Pharma, Inc. Common Stock shares in Q1 2018, an estimated $127K.
Zacks Investment Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2014 and held it in 11 quarters.
Zacks Investment Management's Lumos Pharma, Inc. Common Stock position peaked at $950K in Q1 2015.
126 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2018.

Based on Zacks Investment Management's 13F filing for Q1 2018, filed 14 May 2018.